SDD Launch: Selective Digestive Decontamination Implementation Service for Low-Resistance ICUs
A service to help ICUs start a specific gut-cleaning treatment to prevent sepsis in patients on ventilators.
A turnkey implementation service that helps ICUs with low antimicrobial resistance adopt selective decontamination of the digestive tract for ventilated sepsis patients — local-resistance eligibility check, topical-plus-short-IV protocol, and outcome monitoring — per the 2026 guidelines' new recommendation.
Concept
SDD Launch is a turnkey implementation service that lets hospital ICUs act on the 2026 SSC guidelines' brand-new suggestion to use selective decontamination of the digestive tract (SDD) in mechanically ventilated adults with sepsis or septic shock — but only in units with a low prevalence of antimicrobial resistance. SDD consists of nonabsorbable topical antimicrobials applied to the oropharynx and upper GI tract plus a short course of broad-spectrum IV antimicrobials, deliberately eliminating pathogenic aerobic bacteria while preserving the anaerobic gut flora essential to digestion and immune function. The service has one gate and one protocol: (1) an eligibility assessment using the ICU's own microbiology data to confirm low local AMR prevalence — the recommendation's explicit precondition; and (2) a ready-to-run SDD protocol covering formulation sourcing or compounding of the oropharyngeal and enteral preparations, the short IV course, patient selection criteria, staff training, and a monitoring dashboard tracking ventilator-associated infections, bloodstream infections, and resistant isolates. The single wedge: SDD is essentially absent from most US ICUs despite the new guideline support, because no hospital has the formulation, protocol, and eligibility check sitting on a shelf — this service supplies them as one adoptable package.
Why now
- Statement 41 of the 2026 SSC guidelines is entirely new: for mechanically ventilated adults with sepsis or septic shock in units with low prevalence of antimicrobial resistance, the panel suggests SDD (conditional recommendation, moderate certainty).
- The guideline's meta-analysis showed a probable reduction in short-term mortality and — counter to the long-standing concern that SDD breeds resistance — a possible reduction in antimicrobial resistance, removing the principal historical objection to adoption.
- The regimen is multi-part (topical oropharyngeal and GI decontamination plus a short IV course) and explicitly conditioned on local resistance prevalence, so adoption requires an implementation product rather than a journal citation; nothing off-the-shelf currently exists for US hospitals.
Written by GLM · 10 Oct 2026
AI assessment
A highly focused implementation service that capitalizes on a specific, new clinical guideline to solve a concrete operational gap in ICU infection control.
- Evidence strength 5/5
- The idea is directly derived from a specific, new recommendation (Statement 41) in the 2026 SSC guidelines, including the necessary preconditions and the specific multi-part regimen.
- Market pull 4/5
- ICUs have high urgency to reduce ventilator-associated infections and mortality, and the endorsement by the SSC provides a powerful catalyst for adoption.
- Novelty & moat 5/5
- Unlike the listed catalog ideas which focus on prehospital screening or probiotics, this is a first-mover implementation service for a brand-new clinical standard.
- Feasibility 4/5
- The MVP is a service-based protocol and dashboard; the primary challenge is the logistics of compounding/sourcing the specific antimicrobials.
- Wedge clarity 5/5
- The wedge is extremely sharp: a specific eligibility check for low-resistance ICUs followed by a turnkey protocol for a new guideline.
- Simplicity / focus 5/5
- The product is a single, focused implementation package rather than a broad platform, avoiding scope creep.
Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Intermountain Healthorganization
A US system with strong antimicrobial stewardship and comparatively low endemic resistance in its ICUs — exactly the low-AMR units the new SDD suggestion applies to — making it a natural early adopter.
- Vanderbilt University Medical Centerorganization
A leading sepsis research center; an implementation-ready SDD program with outcome monitoring lets it evaluate and refine the new recommendation in practice rather than in theory.
- Fresenius Kabicompany
A hospital-pharmaceutical supplier that could manufacture or compound the oropharyngeal and enteral topical preparations plus the short-course IV agents the protocol requires, creating a new product line.
- Society of Critical Care Medicineorganization
Co-sponsor of the SSC guidelines; a turnkey implementation partner with a monitoring dashboard translates its new statement 41 into measurable practice change and adoption data.
Research it builds on
- Executive Summary: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026Hallie C. Prescott, Massimo M. Antonelli, Waleed Alhazzani et al. · 2026 · 138 citationsAll ideas from this paper →